Table 2.
Subject characteristics
| Cohort | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| 2B3–201 dose | 150 mg | 300 mg | 450 mg | 450 mg | 300 mg | 450 mg | 450 mg |
| Population | Healthy males | Healthy males | Healthy males | Healthy males | Healthy males | Healthy males | Healthy females |
| Age (years), mean (range) | 25 (20–30) | 24.9 (19–36) | 25.3 (20–45) | 21.3 (19–25) | 25.5 (20–35) | 19.8 (18–23) | 23 (20–30) |
| Weight (kg), mean (range) | 77.6 (66–95) | 71.3 (66–77) | 75.5 (68–88) | 81.1 (68.9–116.6) | 71.0 (59.8–85.6) | 72.1 (65.9–77.8) | 66.8 (54.4–81.2) |
| Height (cm), mean (range) | 183.9 (177–191) | 179.9 (159–189) | 183.4 (165–194) | 184.9 (178.4–199.6) | 177.3 (165.0–188.2) | 184.2 (179.2–191.5) | 171.5 (162.7–179.0) |
| BMI (kg m –2 ), mean (range) | 23.0 (20–28) | 22.1 (20–26) | 22.6 (18–26) | 23.5 (21.5–29.3) | 22.7 (18.4–25.2) | 21.2 (20.2–23.1) | 22.8 (19.1–26.9) |
| Number of subjects | 6 | 6 | 6 (1 dropout) | 6 | 6 | 5 (1 dropout) | 6 (2 dropouts) |
BMI, body mass index